50
Participants
Start Date
May 16, 2017
Primary Completion Date
April 11, 2022
Study Completion Date
April 11, 2022
Miransertib
Miransertib capsules administered orally at an initial dose of 15 mg/m\^2 or 25 mg/m\^2 QD and then titrated up to 25 mg/m\^2 or 35 mg/m\^2 QD at the investigator's discretion.
Hunter Genetics ( Site 0201), Waratah NSW
Children's Hospital of Atlanta ( Site 0107), Atlanta
Cincinnati Children's Hospital Medical Center ( Site 0102), Cincinnati
Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 0101), Chicago
Texas Children's Hospital ( Site 0104), Houston
Universita di Catania ( Site 0088), Catania
Seattle Childrens Hospital ( Site 0103), Seattle
Boston Children's Hospital ( Site 0089), Boston
Ospedale Pediatrico Bambino Gesu ( Site 0087), Rome
Fondazione Policlinico Universitario A. Gemelli ( Site 0052), Roma
Hospital Sant Joan ( Site 0601), Esplugues de Llobregat
Collaborators (1)
Worldwide Clinical Trials
OTHER
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
INDUSTRY